Claims
- 1. A compound of the formula:
- wherein R.sup.1 is:
- (a) a pharmaceutically acceptable cation;
- (b) a branched or straight chain alkyl group of 1 to 6 carbon atoms;
- (c) hydrogen;
- (d) a NR.sup.3.sub.2 group with the adjacent connecting oxygen omitted, wherein each R.sup.3, which may be identical or different, is hydrogen, a methyl or an ethyl group;
- R.sup.2 is:
- (a) an aliphatic hydrocarbon group of 1 to 8 carbon atoms which is saturated or optionally contains 1 or 2 carbon-carbon unsaturated bond(s) and optionally substituted by a methyl, dimethyl or fluorine;
- (b) a cycloaliphatic group of 4 to 7 ring carbon atoms which is saturated or optionally contains 1 carbon-carbon unsaturated bond and optionally has a ring carbon atom replaced by sulphur or oxygen;
- (c) a phenyl group;
- (d) a benzyl group;
- (e) a --(CH.sub.2).sub.m --R.sup.4 group wherein m is an integer from 1 to 6 and R.sup.4 is an alkoxy or cycloalkyl group; wherein the OH group on carbon 15 is optionally on carbon 16;
- X is OCH.sub.3 or OC.sub.2 H.sub.5 ;
- wherein the hydroxy group on carbon 15 is in either the R or S configuration.
- 2. The compound of claim 1 wherein X is methoxy and R.sup.1 is a t-butyl or methyl group and R.sup.2 is an aliphatic hydrocarbon group of 1 to 8 carbon atoms which is saturated or optionally contains 1 or 2 unsaturated bond(s) and is optionally substituted by one or two methyl groups or fluoro.
- 3. A compound according to claim 2 which is 1,1-Dimethylethyl(3a.beta.,6a.beta.)[2-fluoro-2-[hexahydro-5.alpha.-hydroxy-4.beta.-(3S*-hydroxy-1E-octenyl)-2R,2.alpha.-methoxy-2H-cyclopenta-[b]furanyl]ethoxy]acetate and its methoxy epimer.
- 4. A compound according to claim 1 which is Methyl (3a.beta.,6a.beta.)[2-fluoro-2-[hexahydro-5.alpha.-hydroxy-4.beta.-(3S*-hydroxy-4-methyl-1E-octen-6-ynyl)-2R,2.alpha.-methoxy-2H-cyclopenta[b]furanyl]ethoxy]acetate.
- 5. The compound of claim 1 wherein R.sup.1 is methyl, ethyl, a Na cation or NH.sub.2 ; and R.sup.2 is a cycloaliphatic group of 4 to 7 ring carbon atoms which is saturated or optionally contains 1 carbon-carbon unsaturated bond and optionally has a ring carbon atom replaced by sulfur or oxygen.
- 6. A compound according to claim 5 which is Ethyl (3a.beta.,6a.beta.)[2-fluoro-2-[hexahydro-5.alpha.-hydroxy-4.beta.[3S*-hydroxy-3-(tetrahydro-2H-pyran-2yl)-IE-propenyl]-2R,2.alpha.-methoxy-2H-cyclopenta[b]furanyl]ethoxy]acetate.
- 7. A compound according to claim 5 which is Methyl (3a.beta.,6a.beta.)[2-[4.beta.-(3S*-cyclopentyl-3-hydroxy-1E-propenyl)hexahydro-5.alpha.-hydroxy-2R,2.alpha.-methoxy-2H-cyclopenta[b][furanyl]-2S*-fluoroethoxy]acetate.
- 8. A compound of the formula: ##STR23## wherein R.sup.1 is: (a) a pharmaceutically acceptable cation;
- (b) a branched or straight chain alkyl group of 1 to 6 carbon atoms;
- (c) hydrogen;
- (d) a NR.sup.3.sub.2 group with the adjacent connecting oxygen omitted, wherein each R.sup.3, which may be identical or different, is hydrogen, a methyl or an ethyl group;
- R.sup.2 is:
- (a) a cycloaliphatic group of 4 to 7 ring carbon atoms which is saturated or optionally contains one carbon-carbon unsaturated bond and optionally has a ring carbon atom replaced by sulphur or oxygen;
- (b) a --(CH.sub.2).sub.m --R.sup.4 group wherein m is an integer from 1 to 6 and R.sup.4 is an alkoxy or cycloalkyl group; wherein the OH group on carbon 15 is optionally on carbon 16;
- wherein the hydroxy group on carbon 15 is in either the R or S configuration.
- 9. The compound according to claim 8 wherein R.sup.1 is a methyl group, an ethyl group, a Na cation or NH.sub.2 and R.sup.2 is a cycloaliphatic group of 4 to 7 ring carbon atoms which is saturated or optionally has 1 unsaturated bond and/or optionally 1 carbon replaced by sulphur or oxygen.
- 10. A compound according to claim 9 which is Methyl (3aS,3a.beta.,6a.alpha.)[2-[4.alpha.-(3S*-cyclopentyl)-3-hydroxy-1E-propenyl]hexahydro-5.beta.-hydroxy-2H-cyclopenta[b]furan-2Z-ylidene]-2-fluoroethoxy]acetate.
- 11. A compound according to claim 9 which is (3aS,3a.alpha.,6a.alpha.)[2-[4.alpha.-(3S*-Cyclopentyl-3-hydroxy-1E-propenyl)]hexahydro-5.beta.-hydroxy-2H-cyclopenta[b]furanyl-2Z-ylidene]-2-fluoroethoxy]acetic acid sodium salt.
- 12. A compound according to claim 9 which is (3aS,3a.alpha.,6a.alpha.)[2-[4.alpha.-(3S*-cyclopentyl-3-hydroxy-1E-propenyl)]hexahydro-5.beta.-hydroxy-2H-cyclopenta[b]furan-2Z-ylidene]-2-fluoroethoxy]acetamide.
- 13. A compound according to claim 8 which is Ethyl (3aS,3a.alpha.,6a.alpha.)[2-fluoro-2-[hexahydro-5.beta.-hydroxy-4.alpha.-[3S*-hydroxy-3(tetrahydro-2H-pyran-2-yl)-1E-propenyl]-2H-cyclopenta[b]furan-2Z-ylidene]ethoxy]acetate.
Parent Case Info
This is a continuation of application Ser. No. 565,250, filed Dec. 23, 1983, now U.S. Pat. No. 4,579,958.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4324730 |
Fried |
Apr 1982 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
565250 |
Dec 1983 |
|